Enjoy complimentary customisation on priority with our Enterprise License!
The global chronic kidney disease (CKD) drugs market size is estimated to grow by USD 3.81 billion at a CAGR of 4.77% between 2023 and 2028.
Growing awareness about the importance of the early detection and diagnosis of CKD is an important driver propelling the growth of the global CKD drugs market. Public health campaigns, medical education initiatives, and raised access to information related to the importance of treating chronic diseases, such as CKD, have collectively elevated awareness regarding the risk factors and symptoms associated with CKD. Furthermore, early detection is important in controlling CKD effectively, as interventions at the early stages can help slow down disease progression and mitigate difficulties. The focus on routine screenings, mainly for people with risk factors such as diabetes and hypertension, has become a focal point of healthcare strategies on CKD across the globe. Consequently, rising awareness about the significance of the early detection and diagnosis of CKD is anticipated to fuel the growth of the market during the forecast period.
Technavio has segmented the market into Drug Class, Route Of Administration, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.
_drugs_market_size_abstract_2023_v1.jpg.webp?v4.1.20)
To learn more about this report, Request Free Sample
The market share growth by the erythropoietin stimulating agents segment will be significant during the forecast period. ESAs play an important role in the management of CKD by managing the issue of anemia, a typical complication associated with impaired kidney function. In CKD patients, the lowered ability of the kidneys to produce erythropoietin leads to anemia, contributing to fatigue and a reduced oxygen-carrying capacity in the blood. ESAs help relieve anemia by stimulating the bone marrow to produce more red blood cells, thereby improving hemoglobin levels and alleviating the symptoms related to anemia.
_drugs_market_segments_abstract_2023_v2.jpg.webp?v4.1.20)
Get a glance at the market contribution of various segments Download PDF Sample
The erythropoietin stimulating agents segment was valued at USD 4.0 billion in 2018. Several pharmaceutical firms provide the ESA class of drugs as part of their product portfolios. In addition, ESAs include an important role in the therapeutic approach for managing anemia in CKD patients, improving their quality of life, and addressing a significant aspect of the disease. Consequently, the rising use of the ESA class of drugs, owing to their benefits in treating CKD-induced anemia, is expected to drive the growth of the chronic kidney disease drugs market during the forecast period.
The oral route of administration plays an important role in the delivery of medications for the management of CKD. The oral route of administration is a preferred and commonly used approach for CKD drugs, delivering comfort and ease of use for patients undergoing prolonged treatment for CKD. The oral route is particularly suitable for drugs that require systemic distribution and those aimed at addressing conditions or complications associated with CKD, such as hypertension, anemia, and mineral and bone disorders. In addition, the increasing consumption of oral medications for CKD is expected to drive the growth of the oral segment of the chronic kidney disease drugs market during the forecast period.
The subcutaneous route of administration is a vital method for giving medications for the management of CKD. Subcutaneous administration is often used for CKD drugs that require a steady and sustained release, therefore delivering a more prolonged therapeutic effect. Compared with oral medications, this allows the medication to enter the bloodstream more quickly; however, in the case of anemia, it might take a few weeks for the body to start making more red blood cells. Furthermore, Aranesp (darbepoetin alfa) and Procrit (epoetin alfa) are the two main injectable treatment options currently available for anemia in patients with CKD. Thus, such factors will fuel the growth of the subcutaneous segment of the market during the forecast period.
_drugs_market_regions_abstract_2023_geo_v2.jpg.webp?v4.1.20)
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.